PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial

Julia C Dettinger, John Kinuthia, Jillian Pintye, Nancy Mwongeli, Laurén Gómez, Barbra A Richardson, Ruanne Barnabas, Anjuli D Wagner, Gabrielle O'Malley, Jared M Baeten, Grace John-Stewart, Julia C Dettinger, John Kinuthia, Jillian Pintye, Nancy Mwongeli, Laurén Gómez, Barbra A Richardson, Ruanne Barnabas, Anjuli D Wagner, Gabrielle O'Malley, Jared M Baeten, Grace John-Stewart

Abstract

Introduction: Women in regions with high HIV prevalence are at high risk of HIV acquisition during pregnancy and postpartum, and acute maternal HIV contributes a substantial proportion of infant HIV infections. Pre-exposure prophylaxis (PrEP) could prevent HIV during pregnancy/postpartum; however, identifying women who would most benefit from PrEP in this period is challenging. Women may not perceive risk, may not know partner HIV status and partners may have external partners during this period. PrEP offer in pregnancy could be universal or risk guided.

Methods and analysis: The PrEP Implementation for Mothers in Antenatal Care (PrIMA) study is a cluster randomised trial that aims to determine the best model for PrEP implementation in pregnancy, among women attending public sector maternal child health clinics in Western Kenya (HIV prevalence >25%). Twenty clinics are randomised to either universal PrEP offer following standardised counselling ('Universal arm' 10 clinics) or risk screening with partner self-test option ('Targeted arm' 10 clinics). Four thousand women will be enrolled and followed through 9-month postpartum. The primary analysis will be intention to treat. Outcomes reflect the balance between HIV preventive effectiveness and avoiding unnecessary PrEP exposure to women at low risk and include: maternal HIV incidence, PrEP uptake, PrEP adherence, PrEP duration, 'appropriate' PrEP use (among women with objective evidence of potential risk), infant birth outcomes, infant growth and partner self-testing uptake. To better understand the feasibility and acceptability of the provision of PrEP in these settings, qualitative interviews and cost-effectiveness analyses will be conducted.

Ethics and dissemination: The protocol was approved by the institutional review boards at Kenyatta National Hospital and the University of Washington. An external advisory panel monitors adverse and social harm events. Results will be disseminated through peer-reviewed journals, presentations at local and international conferences to national and global policy makers, community and participants.

Trial registration number: NCT03070600.

Keywords: HIV; cluster randomised trial; postpartum period; pre-exposure prophylaxis (PrEP); pregnancy.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Adapted CONSORT diagram for cluster randomised trials. ANC, antenatal care; CONSORT, Consolidated Standards of Reporting Trials.
Figure 2
Figure 2
PrIMA study sites. PrIMA, PrEP Implementation for Mothers in Antenatal Care.
Figure 3
Figure 3
PrIMA enrolment visit procedures by study arm, and interventions and assessments throughout the study. PrEP, pre-exposure prophylaxis; PrIMA, PrEP Implementation for Mothers in Antenatal Care.
Figure 4
Figure 4
Risk assessment for targeted arm participants. PrEP, pre-exposure prophylaxis.

References

    1. Drake AL, Wagner A, Richardson B, et al. . Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med 2014;11:e1001608 10.1371/journal.pmed.1001608
    1. Kinuthia J, Drake AL, Matemo D, et al. . HIV acquisition during pregnancy and postpartum is associated with genital infections and partnership characteristics. AIDS 2015;29:2025–33. 10.1097/QAD.0000000000000793
    1. Thomson KA, Hughes J, Baeten JM, et al. . Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis 2018;218:16–25. 10.1093/infdis/jiy113
    1. Dunn DT, Newell ML, Ades AE, et al. . Risk of human immunodeficiency virus type 1 transmission through breastfeeding. The Lancet 1992;340:585–8. 10.1016/0140-6736(92)92115-V
    1. Lockman S, Creek T. Acute maternal HIV infection during pregnancy and breast-feeding: substantial risk to infants. J Infect Dis 2009;200:667–9. 10.1086/605124
    1. Fonner VA, Dalglish SL, Kennedy CE, et al. . Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 2016;30:1973–83. 10.1097/QAD.0000000000001145
    1. Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir Disoproxil Fumarate Safety for Women and their Infants during Pregnancy and Breastfeeding: Systematic Review. AIDS 2016;31(2):213–32.
    1. Wang L, Kourtis AP, Ellington S, et al. . Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis 2013;57:1773–81. 10.1093/cid/cit601
    1. Mugwanya KK, Hendrix CW, Mugo NR, et al. . Pre-exposure prophylaxis use by breastfeeding HIV-uninfected women: a prospective short-term study of antiretroviral excretion in breast milk and infant absorption. PLoS Med 2016;13:e1002132 10.1371/journal.pmed.1002132
    1. Ministry of Health NASCOP. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya 2016. Nairobi, Kenya: NASCOP, 2016.
    1. World Health Organization. WHO Technical brief: Preventing HIV during pregnancy and breastfeeding in the context of pre-exposure prophylaxis (PrEP). Geneva: World Health Organization, 2017.
    1. Kuhns LM, Hotton AL, Schneider J, et al. . Use of Pre-exposure Prophylaxis (PrEP) in young men who have sex with men is associated with race, sexual risk behavior and peer network size. AIDS Behav 2017;21:1376–82. 10.1007/s10461-017-1739-0
    1. Rendina HJ, Whitfield TH, Grov C, et al. . Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): Findings from a large cohort of gay and bisexual men in the U.S. Soc Sci Med 2017;172:115–23. 10.1016/j.socscimed.2016.10.030
    1. Ridgway JP, Almirol EA, Bender A, et al. . Which patients in the emergency department should receive preexposure prophylaxis? Implementation of a predictive analytics approach. AIDS Patient Care STDS 2018;32:202–7. 10.1089/apc.2018.0011
    1. Pintye J, Drake AL, Kinuthia J, et al. . A risk assessment tool for identifying pregnant and postpartum women who may benefit from preexposure prophylaxis. Clin Infect Dis 2017;64:751–8. 10.1093/cid/ciw850
    1. Ministry of Health NACC. Kenya AIDS Response Progress Report 2016. 2016.
    1. Kenya National Bureau of Statistics, Ministry of Health, National AIDS Control Council, Kenya Medical Research Institute, National Council for Population and Development, The DHS Program, ICF International. Kenya Demographic and Health Survey 2014. Nairobi, Kenya, 2015.
    1. Ivers NM, Halperin IJ, Barnsley J, et al. . Allocation techniques for balance at baseline in cluster randomized trials: a methodological review. Trials 2012;13:120 10.1186/1745-6215-13-120
    1. Thirumurthy H, Masters SH, Mavedzenge SN, et al. . Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study. Lancet HIV 2016;3:e266–74. 10.1016/S2352-3018(16)00041-2
    1. Kosack CS, de Kieviet W, Bayrak K, et al. . Evaluation of the Nova StatSensor® Xpress(TM) Creatinine point-of-care handheld analyzer. PLoS One 2015;10:e0122433 10.1371/journal.pone.0122433
    1. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age. Acta Paediatr Suppl 2006;450:76–85.
    1. Anderson PL, Liu AY, Castillo-Mancilla JR, et al. . Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy. Antimicrob Agents Chemother 2018;62 10.1128/AAC.01710-17
    1. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. . Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses 2013;29:384–90. 10.1089/aid.2012.0089
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81. 10.1016/j.jbi.2008.08.010
    1. Morse JM. Determining Sample Size. Qual Health Res 2000;10:3–5. 10.1177/104973200129118183
    1. Marshall MN. Sampling for qualitative research. Fam Pract 1996;13:522–6. 10.1093/fampra/13.6.522

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する